Novavax reports positive DSMB analysis of Phase III for RSV vaccine

Novavax Inc. (NASDAQ:NVAX) presented results from an "informational analysis" of the Phase III Prepare trial of its RSV F vaccine to prevent respiratory

Read the full 231 word article

User Sign In